VHH Target Pipeline · AlpalifeBio

VHH Target Development PipelineNANOBODY TARGET PORTFOLIO

Built on AlpalifeBio's in-house alpaca nanobody (VHH) discovery platform, this portfolio covers 201 client-designed targets across oncology, immunology, metabolism, fibrosis and CNS delivery — ready as universal targeting modules for ADCs, multispecific antibodies, CAR-T/CAR-NK, radiopharmaceuticals, functional biologics and targeted delivery, maturing from antibody discovery through cell-based / functional validation. Licensing and co-development inquiries are welcome.

Pipeline Overview

AT A GLANCE

Potential Application Distribution

Research Area Distribution

Target Details

TARGET DETAILS

No.	Target	Area	Key Indications	Potential Applications	Asset Stage

No matching targets. Try other keywords or filters.

Stage definitions — Antibody Discovery: immunization, library construction, screening or early hit identification; Antibody Expression: VHH sequences obtained, recombinant expression in progress or usable samples available; Validation Complete: cell-level, affinity and/or functional validation data available, or in advanced validation.
This portfolio is available for licensing and co-development; detailed sequence, affinity, epitope and functional data can be provided under appropriate collaboration arrangements.
This page is for research and business discussion only and does not constitute any commitment regarding efficacy or approval. Data as of Oct 2026.